Neuronyx, Inc.

Usage of adult bone marrow-derived stem cells to repair, regenerate and remodel tissue in acute and chronic disease settings.

Neuronyx, Inc. is a development-stage biopharmaceutical company, which was founded by Hubert J.P. Schoemaker (Centocor, Inc.) in 1999.

Anne Faulkner Schoemaker, CEO
Francis Conway, CFO, VP for Finance and Administration
Joseph Wagner, Ph.D., VP of Cellular Therapy
Richard Gore, VP of Manufacturing

John Groom
Michael Henos
Anne Faulkner Schoemaker
Lawrence Steinman, M.D.
Gary Kurtzman, M.D.

1 Great Valley Parkway, Suite 20
Malvern, PA 19355
USA
Phone: +1-610-240-4150
Fax: +1-610-240-4175

The company is focused on neurological disease research and commercialises novel therapies to treat patients with debilitating brain and central nervous system (CNS) disorders. Neuronyx has developed a unique population of human adult bone marrow-derived stem cells (hABM-SCs). Neuronyx’s advanced cell product development programs - which involve collaborations with researchers from Thomas Jefferson University in Philadelphia and Johns Hopkins University in Baltimore - target brain tumours and Parkinson’s disease. The main program of Neuronyx, in collaboration with Centocor/Johnson & Johnson, is focused on the use of hABM-SCs for cardio-related disease applications. Neuronyx has developed techniques for the isolation and expansion of hABM-SCs.

Neuronyx has conducted studies that demonstrate the preclinical efficacy of hABM-SCs in improving cardiac function following myocardial infarction. Additional studies are currently in progress.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.